Antiviral activity of micafungin against enterovirus 71

作者：Kim Chonsaeng; Kang Hyunju; Kim Dong eun; Song Jae Hyoung; Choi Miri; Kang Mingu; Lee Kyungjin; Kim Hae Soo; Shin Jin Soo; Jeong Hyejeong; Jung Sunhee; Han Sang Bae; Kim Jong Heon; Ko Hyun Jeong; Lee Chong Kyo; Kim Meehyein; Cho Sungchan^*

来源：Virology Journal, 2016, 13(1): 99.

DOI：10.1186/s12985-016-0557-8

• Enterovirus
• Enterovirus 71 (EV71)
• Micafungin
• FDA-approved drug
• Antiviral drug

Background: Enterovirus 71 (EV71) is a major causative agent of hand-foot-mouth disease (HFMD) and also causes severe neurological complications, leading to fatality in young children. However, no effective therapy is currently available for the treatment of this infection.
Methods: We identified small-molecule inhibitors of EV71 from a screen of 968 Food and Drug Administration (FDA)-approved drugs, with which clinical application for EV71-associated diseases would be more feasible, using EV71 subgenomic replicon system. Primary hits were extensively evaluated for their antiviral activities in EV71-infected cells.
Results: We identified micafungin, an echinocandin antifungal drug, as a novel inhibitor of EV71. Micafungin potently inhibits the proliferation of EV71 as well as the replication of EV71 replicon in cells with a low micromolar IC50 (similar to 5 mu M). The strong antiviral effect of micafungin on EV71 replicon and the result from time-of-addition experiment demonstrated a targeting of micafungin on virion-independent intracellular process(es) during EV71 infection. Moreover, an extensive analysis excluded the involvement of 2C and 3A proteins, IRES-dependent translation, and also that of polyprotein processing in the antiviral effect of micafungin.
Conclusions: Our research revealed a new indication of micafungin as an effective inhibitor of EV71, which is the first case reporting antiviral activity of micafungin, an antifungal drug.

• 出版日期2016-6-13